Skip to main content
S&P 5007,651.54-0.25%DOW50,906.05-0.86%NASDAQ26,861.06+0.24%BTC$83,709.00+0.39%ETH$2,682.97+0.18%GOLD$4,189.10+0.22%OIL$90.34+1.07%
Smart Investors Daily
SID Premium
AE

AMEX · AEON

AEON Biopharma, Inc.

Healthcare · Biotechnology

$0.26

Up+$0.04 (+15.83%)

Updated Sep 30, 2026, 9:00 PM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
13.25M
P/E ratio
-4,343.36
Dividend yield
0.00%
52-week range
$0.18 – $1.45
Volume
195.79K
Avg. volume
188.91K

Price performance · AEON

AEON price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 29, 2026

AEON closed at $0.26 after 20 trading sessions, down 6.36% for the selected period.

Last close
$0.26
Period change
-6.36%
Period low
$0.23
Period high
$0.33
Daily close
View OHLC price history
AEON OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 29, 2026$0.2628$0.2649$0.2547$0.259195.79K
Sep 28, 2026$0.2614$0.27$0.26$0.2616312.56K
Sep 25, 2026$0.2621$0.2705$0.2575$0.2636566.52K
Sep 24, 2026$0.2652$0.2685$0.2548$0.2602561.67K
Sep 23, 2026$0.2675$0.2849$0.26$0.26391.29M
Sep 22, 2026$0.2578$0.2654$0.2516$0.262398.53K
Sep 21, 2026$0.255$0.26$0.2426$0.254666.35K
Sep 18, 2026$0.254$0.2668$0.24$0.24252.1M
Sep 17, 2026$0.2439$0.25$0.2321$0.24631.47M
Sep 16, 2026$0.2669$0.2771$0.251$0.2571.51M
Sep 15, 2026$0.278$0.278$0.2514$0.26562.08M
Sep 14, 2026$0.3261$0.345$0.2523$0.28626.19M
Sep 11, 2026$0.298$0.3799$0.2903$0.326931.01M
Sep 10, 2026$0.296$0.3544$0.28$0.29203.62M
Sep 9, 2026$0.248$0.248$0.231$0.231473.87K
Sep 8, 2026$0.2451$0.2451$0.23$0.235157.21K
Sep 4, 2026$0.258$0.2759$0.24$0.2408758.72K
Sep 3, 2026$0.2785$0.2785$0.25$0.2547374.21K
Sep 2, 2026$0.2718$0.2801$0.268$0.271194.55K
Sep 1, 2026$0.2828$0.2867$0.2634$0.2766366.69K

Latest AEON news

The latest Smart Investors Daily articles mentioning AEON.

Stock researchCompany · Overview

AEON research

Overview

Company profile and research snapshot.

Company profile

AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
AEON recent ratings
DateFirmRatingTarget
Aug 14, 2026HC Wainwright & Co.Buy—
Oct 8, 2025Aegis CapitalBuy—
Oct 1, 2024HC Wainwright & Co.Buy—
Aug 14, 2024HC Wainwright & Co.Buy—
Jul 10, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated Results provide additional analytical evidence supporting comparability and establish the basis for AEON’s planned multi-lot comparability study ALISO VIEJO, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to

Yahoo · Aug 31, 2026

AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference

ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026

Yahoo · Aug 24, 2026

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

- Former Deputy Director of the FDA’s Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450 ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By